Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Intravenous Ascorbic Acid in Relapsed/Refractory Lymphoma, CCUS, and CMML
NCT03418038Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Mar 2018
- Primary completion
- Feb 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ascorbic acid in lymphoma, clonal cytopenia of undetermined significance (CCUS), chronic myelomonocytic leukemia (CMML), sponsored by Mayo Clinic. Started Mar 2018; status: recruiting.
02
Drugs
ascorbic acid
03
Conditions
lymphomaclonal cytopenia of undetermined significance (CCUS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03418038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03418038.